GO
Loading...

Eurostar Plans 25% Cut in CO2 by 2012

Eurostar, the passenger train service linking London and mainland Europe, set a target on Tuesday to cut CO2 emissions by 25% per passenger by 2012.

Eurostar said it would make the cut by sourcing power from greener electricity generators, increasing train capacity and improving the efficiency of its rolling stock.

Where Eurostar cannot eliminate CO2 emissions, it will invest in carbon offsetting schemes, it added.

Carbon offsetting allows companies to buy carbon credits from other firms or countries that have reduced emissions.

"Unlike other transport operators, who ask passengers to volunteer to offset CO2 emissions at their own expense, we will bear the cost of making every journey carbon neutral. We will not charge a penny extra," said Eurostar chief executive Richard Brown.

"We do know that a high-speed rail journey is 10 times greener than flying," he added.

Eurostar was owned, when launched, by France's SNCF railway body, Belgium's SNCB and British Rail. The British interests are now held by Eurostar UK (EUKL).

SNCF and SNCB are responsible for the running of Eurostar services on their own territory.

On the British side this is done by the ICRR consortium, which comprises the National Express Group, which has a 40% stake, SNCF with 35%, SNCB with 15% and British Airways with 10%.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Mark Zandi, Moody Analytics; Austan Goolsbee, Booth School of Business, and Lanhee Chen, Stanford University, discuss how layoffs in the energy sector, cold weather, and negative productivity could impact Friday's employment report. I think entitlement spending is a huge problem, says Chen.

  • CNBC's Dominic Chu takes a look at past jobs reports to find which sectors moved higher on positive numbers.

  • Jason Kolbert, Maxim Group, provides perspective on big M&A deals in the biotech space.